Industry News

Jacobs Engineering Group Inc. announced today it was awarded a contract to provide engineering services and procurement for Alnylam Pharmaceuticals’ new manufacturing facility in Norton, Massachusetts. Under the terms of the agreement, Jacobs is providing engineering services and procurement for the multi-product facility being built to supply RNA interference-based therapeutics for clinical and commercial needs. In making the announcement,..."/>
Jacobs Wins Contract for New Alnylam Biopharmaceutical Manufacturing Facility
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported key business updates and financial results for the quarter..."/>
Minerva Neurosciences Reports Second Quarter 2016 Financial Results and Business Updates
Genocea Biosciences, Inc., a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today reported corporate highlights and financial results for the second quarter ended June 30, 2016.. "Full results from the Phase 2 dose optimization trial evaluating GEN-003, our immunotherapy for genital herpes, were showcased at ASM Microbe 2016 in June. The data show that a single course of treatment has significant and durable..."/>
Genocea Reports Second Quarter 2016 Financial Results
Palatin Technologies, Inc. today announced that the last patient visits in the Company's reconnect studies, consisting of two pivotal Phase 3 clinical trials of bremelanotide for the treatment of female hypoactive sexual desire disorder, have been completed. "We are very excited with the completion of the last patient visits in our Phase 3 r econnect studies," said Carl Spana, Ph.D., President and Chief Executive Officer of Palatin."/>
Palatin Technologies Announces Completion of All Patient Visits In Phase 3 Clinical Trials of Bremelanotide for Hypoactive Sexual Desire Disorder
Pacira Pharmaceuticals, Inc. today provided updates on EXPAREL ® for postsurgical pain in the United States and announced consolidated financial results for the second quarter ended June 30, 2016.. “The second quarter marked another period of double-digit, year-over-year revenue growth as we advanced multiple..."/>
Pacira Pharmaceuticals, Inc. Reports Second Quarter 2016 Financial Results
MacroGenics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that the Company’ s management will participate in two upcoming investor conferences. The Canaccord Genuity Growth Conference in Boston, Massachusetts. MacroGenics' presentation is..."/>
MacroGenics to Participate in Two Upcoming Investor Conferences
Repligen Corporation, a life sciences company focused on bioprocessing technology leadership, today reported financial results for the second quarter ended June 30, 2016. Detailed in this press release are the Company's performance highlights for the period, followed by updated financial guidance for the year 2016 and access information for today's webcast and conference call. Tony J. Hunt, President and Chief Executive Officer said,“ We continue to..."/>
Repligen Reports Second Quarter 2016 Financial Results
Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that Vicente Anido, Jr., Ph.D., Chief Executive Officer and Chairman of the Board, will present at the Canaccord Genuity Growth Conference on Wednesday, August 10, 2016 at 12:30 p.m. Eastern Time in Boston, MA. Anido will provide an Aerie overview and business update."/>
Aerie Pharmaceuticals to Present at the Canaccord Genuity Growth Conference
Intercept Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat..."/>
Intercept Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update
Abeona Therapeutics, Inc., a leading clinical-stage biopharmaceutical company focused on delivering gene and plasma-therapies for life-threatening rare..."/>
Abeona Therapeutics Announces European Regulatory Approval for Phase 1/2 Gene Therapy Clinical Study for Patients With Sanfilippo Syndrome Type A (MPS IIIA)
Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today reported..."/>
Agios Reports Second Quarter 2016 Financial Results
Trevena, Inc., a clinical stage pharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced financial results for the quarter ended June 30, 2016 and provided an update regarding its ongoing clinical programs. “This quarter marked an important milestone for the company’ s oliceridine..."/>
Trevena Reports Second Quarter 2016 Financial Results and Provides Corporate Update
OTC Markets Group Inc., operator of financial markets for 10,000 U.S. and global securities, today announced Stereotaxis, Inc., a healthcare technology and innovation leader focused on the development of robotic cardiology instrument navigation systems, has qualified to trade on the OTCQX ® Best Market. Stereotaxis, Inc. previously traded on NASDAQ. Stereotaxis, Inc. begins trading today on OTCQX under the symbol "STXS.""/>
OTC Markets Group Welcomes Stereotaxis, Inc. to OTCQX
BioDelivery Sciences International, Inc. announced that it has reached its target number of subjects to be randomized in its multi-center, double-blind, placebo-controlled Phase 2 b study assessing the efficacy and safety of Clonidine Topical Gel in the treatment of pain associated with painful diabetic neuropathy. Based on the timing of randomization of the last patient, BDSI now expects topline results of the study will be available by..."/>
BioDelivery Sciences Announces Randomization Target Reached in Clinical Trial of Clonidine Topical Gel for the Treatment of Painful Diabetic Neuropathy
Akorn Provides Second Quarter 2016 Results
Lexicon Pharmaceuticals, Inc., today reported financial results for the second quarter ended June 30, 2016 and provided an overview of key milestones for the company's lead drug candidates. "We enter the second half of the year with significant momentum, with both telotristat etiprate and sotagliflozin," said Lexicon President and Chief Executive Officer, Lonnel Coats. "We are looking forward to our upcoming PDUFA date of November 30..."/>
Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2016 Second Quarter Financial Results
Curis, Inc., a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, today reported its financial results for the second quarter ended June 30, 2016.. "We are pleased that dosing of patients has started in the Phase 1 trial of CA-170, the first oral, small molecule immune checkpoint inhibitor targeting PD-L1 and VISTA pathways from our collaboration..."/>
Curis Reports Second Quarter 2016 Financial Results
EnteroMedics Inc., the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced financial results for the three months ended June 30, 2016.. "EnteroMedics continues to build momentum into the second half of the year, with a four-fold increase in vBloc procedures seen in the second quarter over the first quarter, all while maintaining..."/>
EnteroMedics Reports Second Quarter 2016 Financial Results
Syneron Medical Ltd., a leading global aesthetic device company, today announced financial results for the three month period ended June 30, 2016.. Second Quarter 2016 Non-GAAP 2 Financial Highlights:. Revenue of $75.0 million, up 2.0% year-over-year, with 11.5% international growth and a 14% decline in North America Emerging products revenue, which represent the Company's strategic growth drivers, grew 46% year-over-year, primarily..."/>
Syneron Medical Reports Second Quarter 2016 Revenue of $75.0 Million and Non-GAAP EPS of $0.09
Inspyr Therapeutics, Inc., a clinical-stage biotechnology company developing novel prodrug therapeutics for the treatment of cancer, announces that Christopher Lowe has been appointed President and Chief Executive Officer, and as a member of the Company’ s Board of Directors. Lowe brings to Inspyr Therapeutics more than 15 years of executive management experience in life sciences as Chief Executive Officer, Chief Financial Officer and Chief Business Officer,..."/>
Inspyr Therapeutics Appoints Christopher Lowe Chief Executive Officer and Director
Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, will provide a corporate update and report financial results for the second quarter ended June 30, 2016 before the NASDAQ market opens on Thursday, August 11, 2016.. The company will not be conducting a conference call in conjunction with this earnings release. Clearside Biomedical, Inc.,..."/>
Clearside Biomedical, Inc. to Report Second Quarter 2016 Financial Results

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Consumer Discretionary645 Articles
Information Technology589 Articles
Financials479 Articles
Health Care336 Articles
Industrials319 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.